Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Altimmune, Inc. (NASDAQ:ALT) has earned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $14.3333.

ALT has been the topic of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a research note on Wednesday, June 24th. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a report on Tuesday, June 2nd. Citizens Jmp cut their price target on Altimmune from $14.00 to $11.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. Wall Street Zen raised Altimmune from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th.

Altimmune Price Performance

ALT stock opened at $3.42 on Monday. The company has a market cap of $665.26 million, a price-to-earnings ratio of -4.38 and a beta of 0.18. The company has a fifty day moving average price of $3.03 and a 200 day moving average price of $3.18. The company has a debt-to-equity ratio of 0.07, a current ratio of 26.78 and a quick ratio of 26.78. Altimmune has a 12 month low of $2.56 and a 12 month high of $6.44.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 31.41%. Sell-side analysts expect that Altimmune will post -0.58 earnings per share for the current year.

Institutional Investors Weigh In On Altimmune

A number of institutional investors have recently bought and sold shares of ALT. Arax Advisory Partners grew its position in Altimmune by 99.7% during the fourth quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after acquiring an additional 4,076 shares during the period. SBI Securities Co. Ltd. increased its position in shares of Altimmune by 27.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after acquiring an additional 1,928 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Altimmune in the first quarter worth about $50,000. Victory Capital Management Inc. purchased a new stake in Altimmune during the 3rd quarter worth approximately $38,000. Finally, BNP Paribas Financial Markets raised its position in shares of Altimmune by 108.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock valued at $39,000 after purchasing an additional 5,253 shares in the last quarter. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.